OverviewSuggest Edit

4D pharma (formerly known as Schosween 18) is a pharmaceutical company focusing on research and development of a new class of medicines known as Live Biotherapeutics. The company develops a proprietary platform that utilizes bacterial functionality for the prevention and treatment of a large of diseases including cancer, gastrointestinal disease, respiratory disease, and central nervous system (CNS) disease. Its products are orally delivered single strains of bacteria that are naturally found in the healthy human gut.

TypePublic
Founded2014
HQLeeds, GB
Website4dpharmaplc.com

Latest Updates

Employees (est.) (Dec 2018)116(+25%)
Job Openings6
Share Price (Oct 2021)£0.7(+8%)
Cybersecurity ratingBMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at 4D pharma

Axel Glasmacher

Axel Glasmacher

Non-Executive Chairman
Glenn Dourado

Glenn Dourado

Chief Business Officer
John Beck

John Beck

Chief Financial Officer
Richard Avison

Richard Avison

Vice President of Finance
Duncan Peyton

Duncan Peyton

Chief Executive Officer
Christophe Carite

Christophe Carite

Senior Vice President of CMC and Process Development
Show more

4D pharma Office Locations

4D pharma has offices in Leeds, Cornhill Road, Cork and Armunia
Leeds, GB (HQ)
9 Bond St
Cornhill Road, GB
Life Sciences Innovation Building
Cork, IE
Room 447, Food Sciences Building, University College Cork, Western Road
Armunia, ES
Parque Tecnológico de León, Parcela, M–10.4
Show all (4)

4D pharma Financials and Metrics

4D pharma Revenue

GBP

Net income (FY, 2018)

(23.7m)

EBITDA (FY, 2018)

(27.2m)

EBIT (FY, 2018)

(28.4m)

Market capitalization (15-Oct-2021)

123.7m

Closing stock price (15-Oct-2021)

0.7

Cash (31-Dec-2018)

16.1m
4D pharma's current market capitalization is £123.7 m.
GBPFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

EBITDA

(3.4m)(10.3m)(11.7m)(20.8m)(27.2m)

EBIT

(3.5m)(10.5m)(12.3m)(20.9m)(28.4m)

Pre tax profit

(2.4m)(10.1m)(11.7m)(24.0m)(28.4m)

Income tax expense

(2.3m)(1.8m)(3.5m)4.7m
GBPFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

31.8m85.4m68.8m11.9m16.1m

Inventories

115.0k28.0k238.0k253.0k290.0k

Current Assets

32.5m90.1m75.0m57.8m33.2m

PP&E

417.0k1.1m3.9m5.2m4.9m
GBPFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(2.4m)(7.7m)(9.9m)(20.4m)(23.7m)

Cash From Operating Activities

(3.8m)(9.1m)(13.5m)(17.2m)(22.9m)

Cash From Financing Activities

36.7m63.8m(14.0k)(11.0k)

Net Change in Cash

28.8m(27.0m)26.9m(16.8m)4.2m
GBPFY, 2014

Financial Leverage

1.1 x
Show all financial metrics

4D pharma Cybersecurity Score

Cybersecurity ratingPremium dataset

B

86/100

SecurityScorecard logo

4D pharma Online and Social Media Presence

Embed Graph

4D pharma News and Updates

4D Pharma Presents Additional Interim Clinical Data From Combination Study for Lead Oncology Candidate

LEEDS, England, March 17, 2020 /PRNewswire/ -- 4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, today announces an update on the previously reported interim data from an ongoing phase I/II clinical trial, in collaboration with MSD, a...

4D Pharma Collaborates With MSD to Develop Live Biotherapeutics for Vaccines

LEEDS, England, Oct. 8, 2019 /PRNewswire/ -- 4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, today announces that the Company has entered into a research collaboration and option to license agreement with MSD, the tradename of Merck &...

4D Pharma Clinical Update - MRx0518 Oncology Programmes

LEEDS, England, April 29, 2019 /PRNewswire/ -- 4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, today announces an update on the clinical progress of its lead oncology Live Biotherapeutic MRx0518. Update on MRx0518 Phase I/II combination ...

4D Pharma Announces Publication of Data Highlighting Immuno-Stimulatory Properties of MRx0518

LEEDS, England, January 29, 2019 /PRNewswire/ -- 4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, today announces the publication of a paper outlining the mechanism and strong immuno-stimulatory effects of MRx0518. The paper 'The...

4D Pharma gibt die Veröffentlichung von Daten zur Hervorhebung der immunstimulierenden Eigenschaften von MRx0518 bekannt

LEEDS, England, January 29, 2019 /PRNewswire/ -- 4D pharma plc (AIM: DDDD), ein biopharmazeutisches Unternehmen, das Pionierarbeit bei der Entwicklung von Live-Biotherapeutika (LBPs, Live Biotherapeutic Products) leistet, gab heute die Veröffentlichung einer Abhandlung bekannt, in der der ...

4D pharma Blogs

Clinical Update - additional interim clinical data from MRx0518 combination study

4D presents an update on the previously reported interim data from its ongoing Phase I/II study of MRx0518 in combination with KEYTRUDA, at Chardan's 2nd Annual Microbiome Medicines Summit

Clinical Update - 4D announce new study of MRx0518 in pancreatic cancer

4D pharma announces opening of a study investigating MRx0518 in combination with radiotherapy in patients with resectable pancreatic cancer

Preliminary safety and clinical observations from its Phase I/II study of MRx0518 in combination with KEYTRUDA®

4D pharma plc (AIM: DDDD), a clinical-stage pharmaceutical company leading the development of Live Biotherapeutics, today announced preliminary safety and clinical observations from an ongoing Phase I/II clinical trial, in collaboration with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ,…

4D pharma collaborates with MSD to develop Live Biotherapeutics for vaccines

4D pharma plc today announces that the Company has entered into a research collaboration and option to license agreement with MSD to discover and develop Live Biotherapeutics for vaccines

Publication of data on neurodegenerative disease programmes

4D pharma announces the publication of data highlighting the neuroprotective properties of MRx0005 and MRx0029

Appointment of independent Non-Executive Director

4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, today announces the appointment of Sandy Macrae, PhD, as an independent Non-Executive Director with immediate effect.
Show more

4D pharma Frequently Asked Questions

  • When was 4D pharma founded?

    4D pharma was founded in 2014.

  • Who are 4D pharma key executives?

    4D pharma's key executives are Axel Glasmacher, Glenn Dourado and John Beck.

  • How many employees does 4D pharma have?

    4D pharma has 116 employees.

  • Who are 4D pharma competitors?

    Competitors of 4D pharma include Macleods Pharmaceuticals, Alkem Laboratories and Octapharma.

  • Where is 4D pharma headquarters?

    4D pharma headquarters is located at 9 Bond St, Leeds.

  • Where are 4D pharma offices?

    4D pharma has offices in Leeds, Cornhill Road, Cork and Armunia.

  • How many offices does 4D pharma have?

    4D pharma has 4 offices.